PubMed

Comparison of two methods of presenting risk information to patients about the side effects of medicines.

Knapp P, Raynor DK, Berry DC.

Qual Saf Health Care. 2004 Jun;13(3):176-80.PMID: 15175486 [PubMed - indexed for MEDLINE]Related articlesFree article

High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.

Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Szarek M, Tsai J; Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group.

JAMA. 2005 Nov 16;294(19):2437-45. Erratum in: JAMA. 2005 Dec 28;294(24):3092. PMID: 16287954 [PubMed - indexed for MEDLINE]Related articlesFree article

Adequacy of patient information on adverse effects: an assessment of patient information leaflets in the UK.

Carrigan N, Raynor DK, Knapp P.

Drug Saf. 2008;31(4):305-12.PMID: 18366241 [PubMed - indexed for MEDLINE]Related articles

Communicating the risk of side effects to patients: an evaluation of UK regulatory recommendations.

Knapp P, Raynor DK, Woolf E, Gardner PH, Carrigan N, McMillan B.

Drug Saf. 2009;32(10):837-49. doi: 10.2165/11316570-000000000-00000.PMID: 19722727 [PubMed - in process]Related articles

A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22.

Wiviott SD, de Lemos JA, Cannon CP, Blazing M, Murphy SA, McCabe CH, Califf R, Braunwald E.

Circulation. 2006 Mar 21;113(11):1406-14. Epub 2006 Mar 13.PMID: 16534008 [PubMed - indexed for MEDLINE]Related articlesFree article

Conversion to atorvastatin in patients intolerant or refractory to simvastatin therapy: the CAPISH study.

Krasuski RA, Doeppenschmidt D, Henry JS, Smith PB, Adinaro J, Beck R, Thompson CM.

Mayo Clin Proc. 2005 Sep;80(9):1163-8.PMID: 16178496 [PubMed - indexed for MEDLINE]Related articlesFree article

Safety of high-dose atorvastatin therapy.

Waters DD.

Am J Cardiol. 2005 Sep 5;96(5A):69F-75F. Review.PMID: 16126026 [PubMed - indexed for MEDLINE]Related articles

Perceived risk of medicine side effects in users of a patient information website: a study of the use of verbal descriptors, percentages and natural frequencies.

Knapp P, Gardner PH, Carrigan N, Raynor DK, Woolf E.

Br J Health Psychol. 2009 Sep;14(Pt 3):579-94. Epub 2008 Nov 6.PMID: 18992183 [PubMed - indexed for MEDLINE]Related articles

Risk factors for rhabdomyolysis with simvastatin and atorvastatin.

Ronaldson KJ, O'Shea JM, Boyd IW.

Drug Saf. 2006;29(11):1061-7.PMID: 17061911 [PubMed - indexed for MEDLINE]Related articles

Risk management of simvastatin or atorvastatin interactions with CYP3A4 inhibitors.

Molden E, Skovlund E, Braathen P.

Drug Saf. 2008;31(7):587-96.PMID: 18558792 [PubMed - indexed for MEDLINE]Related articles

The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study.

Roeters van Lennep HW, Liem AH, Dunselman PH, Dallinga-Thie GM, Zwinderman AH, Jukema JW.

Curr Med Res Opin. 2008 Mar;24(3):685-94. Epub 2008 Jan 25.PMID: 18226326 [PubMed - indexed for MEDLINE]Related articles

Patients' understanding of risk associated with medication use: impact of European Commission guidelines and other risk scales.

Berry DC, Raynor DK, Knapp P, Bersellini E.

Drug Saf. 2003;26(1):1-11. Review.PMID: 12495359 [PubMed - indexed for MEDLINE]Related articles

Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.

Strandberg TE, Feely J, Sigurdsson EL; DISCOVERY study group.

Clin Ther. 2004 Nov;26(11):1821-33.PMID: 15639694 [PubMed - indexed for MEDLINE]Related articles

Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II.

Ballantyne CM, Bertolami M, Hernandez Garcia HR, Nul D, Stein EA, Theroux P, Weiss R, Cain VA, Raichlen JS.

Am Heart J. 2006 May;151(5):975.e1-9.PMID: 16644314 [PubMed - indexed for MEDLINE]Related articles

Heat shock protein antibody titers are reduced by statin therapy in dyslipidemic subjects: a pilot study.

Ghayour-Mobarhan M, Lamb DJ, Vaidya N, Livingstone C, Wang T, Ferns GA.

Angiology. 2005 Jan-Feb;56(1):61-8.PMID: 15678257 [PubMed - indexed for MEDLINE]Related articles

Cognitive impairment associated with atorvastatin and simvastatin.

King DS, Wilburn AJ, Wofford MR, Harrell TK, Lindley BJ, Jones DW.

Pharmacotherapy. 2003 Dec;23(12):1663-7.PMID: 14695047 [PubMed - indexed for MEDLINE]Related articles

Effects of atorvastatin on bone in postmenopausal women with dyslipidemia: a double-blind, placebo-controlled, dose-ranging trial.

Bone HG, Kiel DP, Lindsay RS, Lewiecki EM, Bolognese MA, Leary ET, Lowe W, McClung MR.

J Clin Endocrinol Metab. 2007 Dec;92(12):4671-7. Epub 2007 Aug 28.PMID: 17726081 [PubMed - indexed for MEDLINE]Related articlesFree article

Effectiveness and cost-effectiveness of rosuvastatin, atorvastatin, and simvastatin among high-risk patients in usual clinical practice.

Ohsfeldt RL, Gandhi SK, Fox KM, Stacy TA, McKenney JM.

Am J Manag Care. 2006 Nov;12(15 Suppl):S412-23.PMID: 17112329 [PubMed - indexed for MEDLINE]Related articlesFree article

The causes and effects of socio-demographic exclusions from clinical trials.

Bartlett C, Doyal L, Ebrahim S, Davey P, Bachmann M, Egger M, Dieppe P.

Health Technol Assess. 2005 Oct;9(38):iii-iv, ix-x, 1-152. Review.PMID: 16181564 [PubMed - indexed for MEDLINE]Related articlesFree article

Benefits and menaces related to the use of statins in patients after renal transplantation.

Chmielewski M, Zdrojewski Z, Rutkowski B.

Ann Transplant. 2002;7(2):6-10. Review.PMID: 12416466 [PubMed - indexed for MEDLINE]Related articlesFree article